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Summary
 
Proteins cleaved by interleukin-1
 
b
 
 converting enzyme family proteases during apoptosis are
common targets for autoantibody production in patients with systemic lupus erythematosus
(SLE). We have tested the possibility that proteins phosphorylated in cells undergoing apoptosis
are also targets for autoantibody production in patients with autoimmune disease. Sera from 9/12
patients containing antinuclear antibodies (10/12 meeting diagnostic criteria for SLE or a lupus
overlap syndrome), precipitated new phosphoproteins from lysates derived from Jurkat T cells
treated with apoptotic stimuli (i.e., Fas-ligation, gamma irradiation, ultraviolet irradiation), but
not with an activation (i.e., CD3-ligation) stimulus. Sera derived from individual patients pre-
cipitated different combinations of seven distinct serine-phosphorylated proteins. None of
these phosphoproteins were included in precipitates prepared using sera from patients with dis-
eases that are not associated with autoantibody production or using serum from rheumatoid ar-
thritis patients. Protein phosphorylation precedes, or is coincident with, the induction of DNA
fragmentation, and is not observed when apoptosis is inhibited by overexpression of bcl-2. Se-
rum from four patients precipitated a serine/threonine kinase from apoptotic cell lysates that
phosphorylates proteins of 23-, 34-, and 46-kD in in vitro kinase assays. Our results suggest
that proteins phosphorylated during apoptosis may be preferred targets for autoantibody pro-
duction in patients with SLE.
 
A
 
common feature of autoimmune diseases such as
systemic lupus erythematosus (SLE)
 
1
 
, systemic sclero-
sis, Sjögren’s disease (SD), and mixed connective tissue dis-
ease is the breakdown of tolerance to self antigens. A con-
sequence of this immune dysfunction is the production of
antibodies reactive with multiple self proteins (1). Remark-
ably, the self proteins recognized by these antibodies are
culled from a relatively small subset of total cellular pro-
teins. Protein targets for autoantibody production can be
grouped into distinct classes sharing structural and/or func-
tional properties. One such class is the ribonucleoprotein
(RNP) particles involved in the regulation of RNA metab-
olism. Autoantigens belonging to this class include hetero-
geneous nuclear RNPs, small nuclear RNPs, the Th/To
RNP complex, and the Ro complex (1–5). It is not known
why tolerance to RNP particles is commonly circum-
vented in patients with autoimmune disease.
It was recently reported that substrates for IL-1
 
b
 
 con-
verting enzyme (ICE) family proteases that are cleaved
during apoptosis comprise a second class of proteins that are
commonly recognized by antibodies found in the serum of
patients with autoimmune disease. Autoantigens belonging
to this class include poly (A) ribose polymerase, U1 70-kD
snRNP, DNA-dependent protein kinase (DNA-PK), nuclear
mitotic apparatus protein, and lamin B (6–10). ICE family
proteases function in the effector phase of apoptotic cell
death. Their substrates are commonly proteins involved in
cellular repair processes, suggesting that they may function
to ensure the irreversibility of the programmed cell death
program. Although proteolysis has the potential to create
novel epitopes in protein substrates, most autoantibodies
recognize both native and processed substrates (1). More-
over, only a small subset of the over 100 autoantigens that
have been described are known to undergo proteolysis dur-
ing apoptosis, suggesting that other mechanisms contribute
to the immunogenicity of these proteins (7, 9). Interest-
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temic lupus erythematosus.
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ingly, several proteins, including the U1 70-kD protein,
have been shown to translocate from the nucleus to large
“apoptotic blebs” at the surface of cultured keratinocytes
after UV irradiation (8, 11). This and other observations
raise the intriguing possibility that cells undergoing apopto-
sis are uniquely suited to present modified self proteins to
the immune system in such a way that overcomes normal
mechanisms of peripheral tolerance (12, 13).
The possibility that cells undergoing apoptosis might be
reservoirs of autoantigens led us to examine the possibility that
proteins selectively phosphorylated during apoptosis might
also be commonly recognized by autoantisera derived from
patients with autoimmune disease. Recent results have es-
tablished that inflammatory cytokines (e.g., TNF-
 
a
 
, Fas-
ligand) and environmental stress (e.g., heat shock, UV
light, and x irradiation) are potent triggers of apoptotic cell
death (14–20). Stress-induced apoptosis requires the activa-
tion of a cascade of stress-activated protein (SAP) kinases
that phosphorylate their specific substrates on serine or thre-
onine residues (14–20). Although the relevent substrates for
these kinases are largely unknown, and neither the kinases
nor their substrates have been implicated in the etiology of
autoimmune disease, we found that autoimmune sera from
patients with SLE and lupus overlap syndromes commonly
recognize proteins that are phosphorylated during apopto-
sis. In addition, serum from four of five patients with SLE
or a lupus overlap syndrome were found to selectively pre-
cipitate a serine/threonine kinase from apoptotic cell ex-
tracts. Our results implicate a SAP kinase in phosphoryla-
tion of autoantigens during apoptosis and link a common
protein modification to autoantibody production in pa-
tients with SLE.
 
Materials and Methods
 
Cell Culture.
 
Jurkat cells were grown in 5% CO
 
2
 
 at 37
 
8
 
C us-
ing RPMI 1640 (BioWhittaker, Inc., Walkersville, MD) supple-
mented with 10% heat-inactivated FCS (HI-FCS; Tissue Culture
Biologicals, Tulare, CA) and penicillin and streptomycin (Media-
tech, Inc., Herndon, VA). Cells were grown and harvested at
mid-log phase. Jurkat T cells overexpressing bcl-2 (or empty vector),
a gift from John Reed (The La Jolla Cancer Research Foundation,
La Jolla, CA), were grown in RPMI medium as described above,
and supplemented with G418 (GIBCO BRL, Gaithersburg, MD)
at a final concentration of 500 
 
m
 
g/ml. Protein overexpression was
confirmed by Western blotting before each experiment.
 
Metabolic Labeling.
 
Jurkat cells were incubated at a density of
2 
 
3
 
 10
 
6
 
 cells/ml in labeling medium containing the following:
45% RPMI 1640, 45% RPMI 1640 lacking either phosphate
(GIBCO BRL) or methionine and cysteine (GIBCO BRL), 2 mM
glutamine (Mediatech, Inc.), 5% HI-FCS, and 5% HI-FCS that
had been dialyzed to equilibrium against 10 mM Hepes buffer
(Sigma Chemical Co., St. Louis, MO). 
 
32
 
P-labeled orthophosphate
or 
 
35
 
S-labeled methionine and cysteine (Dupont–New England
Nuclear, Boston, MA) was added at a concentration of 0.1 mCi/ml.
Cells were incubated at 37
 
8
 
C for 10–12 h to allow the cells to
reach a steady state before each treatment, unless otherwise indi-
cated.
 
Cell Lysis.
 
Lysis of cells was performed using nonidet P40
(NP40) (Sigma Chemical Co.) lysis buffer (1% NP40, 150 mM
NaCl, 50 mM Tris, pH 7.8, 1 mM EDTA). NP40 lysis buffer was
supplemented immediately before use with 1 mM sodium vana-
date (Sigma Chemical Co.) and a 1:100 dilution of a 100
 
3
 
 protease
inhibitor cocktail prepared by dissolving 10 mg chymostatin, 1.5
mg leupeptin, 7 mg pepstatin A, 850 mg phenylmethylsulfonyl
fluoride, 500 mg benzamidine, and 5 mg aprotonin in 50 ml of
ethanol by stirring overnight. The solution was sterilized by filtra-
tion and stored at room temperature (21). All chemicals were pur-
chased from Sigma Chemical Co. After addition of 1 ml lysis
buffer, the lysate was incubated on ice for 30 min, centrifuged in
a refrigerated microfuge (5402; Eppendorf Inc., Hamburg, Ger-
many) at 14,000 rpm for 15 min, and the supernatant was imme-
diately used for each experiment.
 
UV Irradiation.
 
Labeled Jurkat cells were placed on 100 
 
3
 
 15
mm polystyrene petri dishes (Nunc, Thousand Oaks, CA) at a
concentration of 2 
 
3
 
 10
 
6
 
 cells/ml and irradiated (Stratalinker
2400; Stratagene Corp., La Jolla, CA) at a distance of 9 cm for 12 s.
After irradiation, cells were incubated at 37
 
8
 
C for the indicated
times before harvesting.
 
Gamma Irradiation.
 
Labeled cells were placed in a 50-ml con-
ical tube and irradiated at a dose of 3,300 rad from a Cesium 137
source using an irradiator (Gammacell 1000; Nordion Interna-
tional, Kanata, Ontario, Canada). After irradiation, cells were
placed in culture dishes at 37
 
8
 
C and incubated for the indicated
times before harvesting.
 
Cellular Activation.
 
Labeled Jurkat cells were treated with the
following antibodies: anti-Fas antibody 7C11 (provided by Michael
Robertson, Indiana University, Bloomington, IN) from hybridoma
supernatant at a final dilution of 1:500, and anti-CD3 antibody
(Coulter Immunology, Hialeah, FL) at a concentration of 5 
 
m
 
g/ml
followed by goat anti–mouse antibody (Jackson ImmunoResearch
Labs., West Grove, PA) at the same concentration. Cells were in-
cubated at 37
 
8
 
C for the indicated times before harvesting.
 
Immunoprecipitation and Western Blot Analysis.
 
Lysates were pre-
cleared once with 25 
 
m
 
l of a 50% solution of protein A–Sepharose
(Pharmacia, Uppsala, Sweden) in PBS and 5 
 
m
 
g rabbit anti–mouse
(RAM) IgG (Jackson ImmunoResearch Labs., West Grove, PA)
for 1 h, followed by two preclears with protein A–Sepharose
overnight. Mouse monoclonal antibodies (5 
 
m
 
g) and 5 
 
m
 
g RAM,
or 3.5–5 
 
m
 
l patient serum alone were used in precipitation exper-
iments. Serum from all Brigham and Women’s Hospital Arthritis
Center (Boston, MA) patients who had a serum sample submitted
to the Brigham and Women’s Hospital Clinical Immunology
Laboratory over an 8-mo-period was collected and stored at
 
2
 
20
 
8
 
C until used. Serum from healthy control patients was a gift
from P. Fraser (Brigham and Women’s Hospital). Diagnoses and
serum characterization were confirmed by chart review by P.J.
Utz. Immunoprecipitations were performed after addition of 1%
BSA (Intergen Co., Purchase, NY) in PBS to a total volume of
500 
 
m
 
l, and rotation in a 4
 
8
 
C cold room for 2–24 h. Comparison
of precipitates showed no difference between incubation times
for periods of up to 72 h. Precipitates were harvested by centri-
fuging for 15 s at 14,000 rpm in a refrigerated Eppendorf mi-
crofuge, washing three times with NP40 lysis buffer supple-
mented with protease inhibitor cocktail, resuspending in SDS
loading buffer with 9% 2-mercaptoethanol, boiling for 5 min, and
electrophoresing on SDS–polyacrylamide gels as described (22).
Proteins were transferred to nitrocellulose (Schleicher & Scheull,
Keene, NH) for Western blotting experiments or to polyvi-
nylidene difluoride (PVDF), (Dupont–New England Nuclear) for
phosphoaminoacid analysis, and either exposed for autoradiogra-
phy or subjected to Western blot analysis as indicated (23). The 
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mouse monoclonal antibody 4D7, anti-bcl-2 (PharMingen, San
Diego, CA) was used for blotting studies at a dilution of 1:1,000.
Nitrocellulose blots were blocked with 3% BSA in PBS overnight
at 4
 
8
 
C. Bands were visualized using RAM conjugated to horse
radish peroxidase (Amersham Corp., Arlington Heights, IL) at a
dilution of 1:7,500 in 1% BSA in PBS, and developed using en-
hanced chemiluminescence performed according to the manufac-
turer’s instructions (Amersham Corp.).
 
Phosphoaminoacid Analysis.
 
Immunoprecipitates that had been
electrophoresed and transferred to PVDF were rinsed thoroughly
with water, exposed for radiography, and appropriate bands ex-
cised with a razor blade. The radiolabeled bands were than sub-
jected to acid hydrolysis as described (24), with the exception that
two-dimensional electrophoresis was performed at 14
 
8
 
C rather
than at 4
 
8
 
C.
 
DNA Fragmentation.
 
Unlabeled Jurkat cells were induced to
undergo apoptosis using the above triggers in parallel experiments
to those using radiolabeled cells. Cells were collected at the indi-
cated times and centrifuged for 5 min at 1,000 rpm. The cell
pellet was lysed by adding 500 
 
m
 
l DNA lysis buffer (20 mM Tris,
pH 7.4, 5 mM EDTA, and 0.4% Triton X-100) and incubating
on ice for 15 min, mixing several times. After centrifuging at
4
 
8
 
C at 14,000 rpm for 5 min, supernatants were extracted with a
25 phenol:24 chloroform:1-isoamyl alcohol mixture (GIBCO
BRL). Next, 100 
 
m
 
l 5 M NaCl and 500 
 
m
 
l isopropanol were
added to each tube before incubating overnight at 
 
2
 
70
 
8
 
C. Sam-
ples were thawed and centrifuged at 14,000 rpm for 5 min,
washed once with 70% ethanol, and dried in a Speed-Vac. Pellets
were resuspended in 30 
 
m
 
l of Tris-EDTA buffer containing 0.1
mg/ml RNase A (Sigma Chemical Co.) and incubated at 37
 
8
 
C
for 30 min. After the addition of 10 
 
m
 
l loading buffer, 10 
 
m
 
l of
each sample, corresponding to 1 million cells per lane, was sepa-
rated on 0.8% agarose gels and visualized by ethidium bromide
staining under UV light.
 
In Vitro Kinase Assays.
 
Individual immunoprecipitates were
washed three times in NP40 lysis buffer, then once with TBS
(150 mM NaCl, 20 mM Tris, pH 7.6) before resuspending in 30
 
m
 
l kinase buffer (20 mM Tris, pH 7.6, 10 mM MgCl
 
2
 
, 2 mM
MnCl
 
2
 
, and 20 
 
m
 
Ci [
 
32
 
P]-gamma ATP [Dupont–New England
Nuclear] 150 mCi/ml) for 30 min at 30
 
8
 
C. The reactions were
terminated by addition of sample buffer and boiling for 5 min.
Proteins were separated on an SDS-PAGE gel before transfer to
PVDF and autoradiography for 2–5 min (25).
 
Results
 
Autoimmune Sera Recognize Proteins Phosphorylated during
Stress-Induced Apoptosis.
 
Serum from 12 random patients
with positive tests for antinuclear antibodies (ANA; defined
as 
 
>
 
1:20 titer on immunofluorescence staining using Hep2
cells as a substrate), as well as serum from 10 healthy con-
trol patients, 5 rheumatoid arthritis patients, and 15 patients
with diseases considered to be unassociated with autoanti-
bodies (including fibrositis, tendonitis, bursitis, chronic fa-
 
Table 1.
 
Characterization of Autoimmune Sera
 
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14
ANA 1:2,560
 
1
 
1:640 1:640 1:640 1:20
 
1
 
1:640 1:640 1:40 1:2560 1:160 ND
 
2
 
Pattern D/C S/D P/D P/D S/D ND S/D D S D/N Nu S/D ND
 
2
 
RF ND ND ND ND ND
 
2
 
ND ND
 
222
 
ND ND ND
Ro
 
1 2221 1 11 2 21 2
 
ND ND
La
 
2 2222 2 22 2 21 2
 
ND ND
Sm
 
2 2222 2 22 2 22 2
 
ND ND
dsDNA
 
1 1222 2 11 2 22 2
 
ND ND
ssDNA
 
1 2211 1 11 2 21 1
 
ND ND
RNP
 
1 2222 2 22 2 21 2
 
ND ND
APLA ND
 
11
 
ND
 
2
 
ND
 
22 2
 
ND ND ND ND ND
Comp
 
¯
 
Nl
 
¯¯
 
Nl
 
­
 
Nl Nl ND Nl Nl Nl ND ND
Disease SLE SLE SLE SLE Over SD Over Over UCTD SLE SLE SLE RA Fib
Bands pp200 pp54 pp54 pp54 pp17 pp46 pp54 pp54 pp54
pp54 pp42 pp17 pp42 pp42 pp42
pp17 pp34 pp34 pp34 pp34
pp23 pp23 pp23
pp17 pp17
Individual patient sera are identified by the numbers above each column. 
 
ANA
 
, antinuclear antibody titer; 
 
Pattern
 
, immunoflourescence staining pat-
tern using Hep 2 cells as substrate (
 
P
 
, peripheral; 
 
D
 
, diffuse or homogeneous; 
 
C
 
, cytoplasmic; 
 
N
 
, homogeneous nuclear; 
 
S
 
, speckled; 
 
Nu
 
, nucleolar);
 
RF
 
, rheumatoid factor; 
 
Ro
 
, RNA binding protein Ro; 
 
La
 
, RNA binding protein La; 
 
Sm
 
, Smith antigen; 
 
dsDNA
 
, double-stranded DNA; 
 
ssDNA
 
,
single-stranded DNA; APLA, antiphospholipid antibody, determined by anticardiolipin ELISA assay; 
 
Comp
 
, complement determined by CH 50 as-
say. Test results are labeled as positive (
 
1
 
); negative (
 
2
 
); normal (NI); not done (ND); increased (
 
­
 
); or decreased (
 
¯
 
). Over, SLE overlap syn-
drome; UCTD, undifferentiated connective tissue disease; Fib, fibrositis. The relative migration of phosphoproteins precipitated using sera derived
from individual patients (derived from Fig. 1 
 
A
 
) are as indicated. 
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tigue syndrome, carpal tunnel syndrome, and osteoarthri-
tis), were chosen from the sera collected as described in
Materials and Methods. All patients with a positive ANA
test were further screened by ELISA for antibodies against
DNA, the Smith complex, Ro, La, and RNP, and the pa-
tients’ charts were reviewed to obtain clinical data sufficient
to establish a diagnosis (1). As summarized in Table 1, most
patients (10/12) met published criteria for either SLE or lu-
pus in association with a second inflammatory condition
(referred to as SLE overlap syndrome; 26). Other condi-
tions were also represented, including SD (patient 6), and
undifferentiated connective tissue disease (patient 9). One
patient with rheumatoid arthritis (RA; patient 13) and a pa-
tient with fibrositis (patient 14) are also presented for com-
parison.
Jurkat cells metabolically labeled with 32P-orthophos-
phate were cultured for 2.5 h in the absence or presence of
a monoclonal antibody reactive with Fas (anti-7C11), solu-
bilized in NP40 lysis buffer, and immunoprecipitated using
the indicated autoimmune or control sera. Immunoprecip-
itates were separated on a 12% SDS–polyacrylamide gel,
transferred to nitrocellulose, and subjected to autoradiograpy.
Fig. 1 A shows that 9/12 ANA1 autoimmune sera, repre-
senting 9/10 SLE or SLE overlap patients, precipitated at least
one new phosphoprotein from cells undergoing Fas-medi-
ated apoptosis compared to untreated cells. The phos-
phorylation of these proteins did not result from a nonspecific,
general increase in kinase activity after Fas engagement, as
32P-labeled,whole cell extracts prepared from untreated and
apoptotic cells were identical when compared on SDS-PAGE
gels (data not shown). The individual phosphoproteins pre-
cipitated by several of the patient sera is strikingly similar in
profile, but variable in intensity of phosphorylation. For
example, serum from patients 1, 2, 3, 4, 8, 11, and 12 pre-
cipitates a protein of z54 kD (pp54) that is weakly phos-
phorylated in untreated cell lysates and strongly phosphory-
lated in lysates from apoptotic cells. Similarly, a 34-kD
protein (pp34) was precipitated using serum derived from
patients 3, 8, 11, and 12; and a doublet of z42 kD (pp42)
was precipitated using serum derived from patients 3, 8, 11,
and 12. None of these phosphoproteins were precipitated
using ANA (2) sera derived from patients 13 or 14, nor us-
ing sera derived from 12 healthy control patients or 4 addi-
tional patients with RA (data not shown). The level of
Figure 1. Human autoim-
mune sera precipitate phospho-
proteins from apoptotic Jurkat
cell lysates. (A) Jurkat cells were
labeled with 32P-orthophos-
phate, treated with the anti-Fas
monoclonal antibody 7C11, and
lysed either before (odd num-
bered lanes) or 2.5 h after (even
numbered lanes) the addition of
antibodies. Proteins were then
precipitated using the indicated
autoimmune serum, separated on
a 12% SDS–polyacrylamide gel,
transferred to nitrocellulose, and
exposed for autoradiography.
Arrows point to new phospho-
proteins in the anti-Fas–treated
lanes. (B) The identical experi-
ment with 35S-labeled cells. Pa-
tient numbers are located above
each figure and correspond to
those in Table 1. Lane numbers
appear beneath the correspond-
ing lane. The relative migration
of molecular size markers in ki-
lodaltons are indicated on the left
side of the gel.847 Utz et al.
phosphorylation of pp42, pp34, and pp17 differed signifi-
cantly between patients (patients 3, 8, 11, and 12) and was
independent of the ANA titer as detected by immunfluo-
rescence (Table 1), suggesting that these phosphoproteins
may be novel and independent of the major proteins re-
sponsible for the immunfluorescence detectable as an
ANA. In addition to the phosphoproteins described above,
three other new phosphoproteins can be seen as bands mi-
Figure 2. Phosphorylation of
autoantigens in response to apop-
totic or mitogenic stimuli. Jur-
kat cells were labeled with 32P-
orthophosphate, triggered with
apoptotic or mitogenic stimuli,
and solubilized using NP40 lysis
buffer at the indicated times be-
fore immunoprecipitation using
sera derived from the indicated pa-
tient.  Immunoprecipitates were
separated on a 12% SDS–polyacry-
lamide gel, transferred to nitrocel-
lulose, and subjected to autora-
diographic analysis. (A) Anti-Fas
treatment; (B) gamma irradiation;
(C) UV irradiation; (D) CD3
cross-linking. Arrows point to
new phosphoproteins. The pa-
tient number is indicated above
each time course. The time, in
hours, from initial exposure to
each stimulus is indicated at the
top of each gel. Lane numbers ap-
pear  beneath the corresponding
lane. The relative migration of
molecular size markers in kilo-
daltons is indicated on the left
side of each panel.848 Phosphorylation of Autoantigens during Apoptosis
grating at the following positions: 17 kD doublet (pp17;
patients 1, 4, 5, 8, and 11), 23 kD (pp23; patients 3, 8, and
11), and 46 kD (pp46; patient 7). A seventh protein mi-
grating between 96 and 200 kD (pp200) was observed for
patient 1 (Fig. 2, A–C).
The preferential inclusion of phosphoproteins in precipi-
tates prepared from apoptotic versus nonapoptotic lysates
could result from de novo phosphorylation of autoantigens,
increased extractability of the phosphoproteins during the
detergent lysis, or recruitment of preexisting or new phos-
phoproteins to the autoantigen complex during apoptosis.
To differentiate between these three possibilities, the ex-
periment shown in Fig. 1 B was performed using cells that
were metabolically labeled with 35S-methionine and cys-
teine in a manner identical to the experiment depicted in
Fig. 1 A, which used cells labeled with 32P-orthophosphate.
In most cases, immunoprecipitates prepared from apoptotic
and nonapoptotic lysates contained similar 35S-labeled pro-
teins. Two exceptions were observed. A 60-kD protein
and a .200-kD protein were included in immunoprecipi-
tates prepared from apoptotic, but not nonapoptotic lysates
using sera derived from patients 10 (Fig. 1 B, lane 20), and
11 (Fig. 1 B, lane 22), respectively (indicated with arrows
on the right side of the panel). Although neither of these
Figure 3. Autoantigen phosphorylation coincides with or precedes the
onset of DNA fragmentation in apoptotic Jurkat cells. Jurkat cells were
triggered to undergo apoptosis and harvested at the indicated times. Each
time point represents a total of 1 million cells. The DNA was prepared as
described in the Materials and Methods, separated on a 0.8% agarose gel
and visualized by staining with ethidium bromide before UV exposure.
(A) Anti-Fas treatment; (B) gamma irradiation; (C) UV irradiation; (D)
anti-CD3 treatment. The time, in hours, from initial exposure to each
stimulus is indicated at the top of each lane. The relative migration of
molecular size markers in kilobases is indicated on the right side of each
panel.
Figure 4. Autoantigens are phosphorylated exclusively on serine resi-
dues during Fas-mediated apoptosis. Jurkat cells were labeled with 32P-ortho-
phosphate, treated with the anti-Fas monoclonal antibody 7C11, and sol-
ubilized using NP40 lysis buffer after 2.5 h. Proteins were then
precipitated with autoimmune serum, separated on a 12% SDS–polyacryl-
amide gel, transferred to PVDF, and exposed for autoradiography. Indi-
vidual phosphoproteins were localized on the membrane, excised, and
subjected to acid hydrolysis. Phosphoamino acids were separated by two-
dimensional electrophoresis in pH 1.9 buffer in the horizontal dimension,
followed by pH 3.5 buffer in the vertical dimension before autoradio-
graphic analysis. Individual proteins correspond to those described in Ta-
ble 1 as follows: (A) patient 1, pp200; (B) patient 1, pp54; (C) patient 7,
pp46; (D) patient 11, pp42; (E) patient 3, pp34; (F) patient 8, pp23; and
(G) patient 11, pp17. Migration of phosphoaminoacid standards are la-
beled with circles as follows: phosphoserine (pS), phosphothreonine (pT),
phosphotyrosine (pY).849 Utz et al.
proteins clearly corresponded to the phosphoproteins iden-
tified in Fig. 1 A, 35S-labeled proteins (Fig. 1 B) migrating
similarly to the phosphoproteins identified in Fig. 1 A were
observed in all cases. Taken together, these results are most
consistent with de novo phosphorylation of autoantigens
during apoptosis.
Phosphorylation of Autoantigens Accompanies Apoptosis, but
Not T Cell Receptor Stimulation. The results shown in Fig. 1
indicate that autoimmune sera preferentially precipitate
proteins phosphorylated in response to Fas ligation. To de-
termine whether these proteins are also phosphorylated dur-
ing apoptosis triggered by stimuli other than Fas ligation,
selected patient sera were used to precipitate 32P-labeled Jur-
kat lysates prepared from cells subjected to apoptotic stimuli
or an activation stimulus for various times. This kinetic
analysis reveals that phosphorylation of autoantigens is in-
duced between 1 and 2.5 h after Fas ligation (Fig. 2 A), be-
tween 2.5 and 4.5 h after gamma irradiation (Fig. 2 B), and
between 1 and 2.5 h after UV irradiation (Fig. 2 C). Indi-
vidual autoantisera precipitate a similar cadre of phospho-
proteins regardless of the apoptotic trigger. In contrast, li-
gation of the T cell receptor complex using a monoclonal
antibody reactive with CD3, a stimulus that induces IL-2
production and enhances proliferation in these cells (data
not shown), induced neither new protein phosphorylation,
nor DNA fragmentation over the course of this experiment
(Figs. 2 D and 3 D). Control sera derived from an individ-
ual without autoimmune disease did not precipitate phos-
phoproteins from apoptotic lysates, nor from lysates pre-
pared from CD3-stimulated cells (Fig. 2, A–D, right). The
kinetics of DNA fragmentation induced by apoptotic or
activation stimuli was also determined. As shown in Fig. 3,
A–D, the onset of DNA fragmentation is approximately
coincident with the phosphorylation of autoantigens re-
gardless of the apoptotic stimulus.
In addition to the phosphorylation of autoantigens dur-
ing apoptosis, selected phosphoproteins appear to be rap-
idly dephosphorylated, and then rephosphorylated in a re-
producible manner over the course of the kinetic assay
(pp17 and pp23; Fig. 2 B, lanes 1–4). The level of basal
phosphorylation of several autoantigens, particularly pp34,
pp23, and pp17 was somewhat variable in each experiment
(e.g., patient 1, Fig. 2, A–D), and appeared to be related to
the initial density of the cells at the time of labeling, with
less dense (and presumably more active) cells labeling more
uniformly (our unpublished observations).
Phosphoaminoacid Analysis of Autoantigens. Since both ty-
rosine kinases and serine/threonine kinases have been im-
plicated in signaling Fas-mediated apoptosis (16, 17, 19, 25,
27–30), we subjected all seven phosphoprotein autoanti-
gens to phosphoaminoacid analysis. In each case, phosphor-
ylation was restricted to serine residues (Fig. 4, A–G), im-
plicating one or more serine/threonine protein kinases in
the phosphorylation of these autoantigens.
A Protein Kinase Activity Is Precipitated from Apoptotic Ly-
sates Using Selected Patient Sera. A cascade of stress-activated
serine/threonine kinases has been implicated in signaling
apoptotic cell death (16, 17, 19, 25, 31). Individual kinases
within this cascade are regulated, in part, by phosphoryla-
tion. It is therefore possible that stress-activated kinases may
be recognized directly by sera derived from patients with au-
toimmune disease, or may be recruited during apoptosis to
preexisting complexes. To test this possibility, lysates from
untreated or anti-Fas–treated Jurkat cells were precipitated
with individual patient sera, and subjected to an in vitro ki-
nase assay as described (25). Five sera were chosen to en-
Figure 5. Autoimmune serum precipitates a serine kinase activity from apoptotic Jurkat lysates. Jurkat cells cultured in the absence (odd numbered
lanes) or presence (even numbered lanes) of anti-Fas were solubilized in NP40 lysis buffer after 2.5 h, and precipitated using 3.5 ml of serum derived from
the indicated patient. Individual precipitates were subjected to an in vitro kinase reaction at 308C for 30 min, separated on an SDS–polyacrylamide gel,
transferred to nitrocellulose, and subjected to autoradiographic exposure for 2 min. (A) In vitro kinase reaction. Serum derived from the patient number
indicated at the top of the figure corresponds to patients described in Table 1. The relative migration of molecular size markers in kilodaltons is indicated
on the right side of the panel. (B) Kinetics of kinase activation after Fas ligation as measured using the in vitro kinase reaction performed on immunopre-
cipitates prepared using serum derived from patient 7. The time in minutes from initial exposure to anti-Fas is indicated at the top of each lane. The po-
sition of pp46 is indicated with an arrow on the left side of the panel. (C) Phosphoamino acid analysis of the in vitro phosphorylated 46-kD protein. Mi-
gration of phosphoamino acid standards are labeled with circles as follows: phosphoserine (pS), phosphothreonine (pT), phosphotyrosine (pY).850 Phosphorylation of Autoantigens during Apoptosis
compass all seven phosphoproteins that had been identified
in the initial screen using in vivo–labeled apoptotic Jurkat
cells (Fig. 1 A and Table 1). In addition, sera from a healthy
control patient and patient 6, whose serum is monospecific
for the Ro protein, were included for comparison. Fig. 5 A
shows that 4/5 ANA 1 patient sera (i.e., patients 3, 7, 8,
and 11) precipitate a kinase whose activity is increased in
apoptotic cell extracts compared to untreated cell extracts.
The healthy control patient and patient 6 were devoid of
kinase activity in this assay. Phosphoproteins migrating at 34
kD (Fig. 5, lanes 4, 6, 8, and 10), 23 kD (lanes 4, 6, 8, and
10), and 46 kD (lane 6) were identified in this assay. The
relative migration of these phosphoproteins is similar to
that of prominant phosphoproteins identified in the in vivo
phosphorylation assay shown in Fig. 1 A. The kinetics with
which the kinase (precipitated using serum from patient 7)
was activated after Fas ligation was correlated with the in-
duction of DNA fragmentation in the experiment shown
in Fig. 5 B. In this experiment, Jurkat cells were cultured in
the presence of anti-Fas monoclonal antibodies for the in-
dicated times before processing for DNA fragmentation
and in vitro kinase activity. The first appearance of pp46 in
the in vitro kinase assay was observed at 90 min (Fig. 5 B),
while DNA fragmentation was first observed 120 min after
Fas ligation (data not shown). Phosphoamino acid analysis
of pp46 showed that the in vitro phosphorylation of pp46
is restricted to serine residues (Fig. 5 C), consistent with the
in vivo results shown in Fig. 4 C. A similar kinetic analysis
targeting pp34 and pp23 using serum from patient 11 (Fig.
5 A, lanes 9 and 10) gave similar results (data not shown).
These results are consistent with the less rigorous time
courses presented in Figs. 2 and 3, and suggest that a
serine/threonine kinase activated by Fas stimulation is
present in the immunoprecipitates from patients 7 and 11 at
a time that precedes the onset of DNA fragmentation.
Bcl-2 Overexpression Blocks Apoptosis and Phosphorylation of
pp46. We next asked whether the phosphorylation of
pp46 could be blocked by overexpression of the bcl-2 pro-
tein, which has been shown to efficiently block apoptosis
induced by multiple apoptotic stimuli, including gamma and
UV irradiation (32–35). In Fig. 6, Jurkat T cells stably trans-
formed with either bcl-2 (left) or empty vector (right) were
labeled with 32P-orthophosphate and subjected to Fas liga-
tion, gamma irradiation, or UV irradiation. Cells were sol-
ubilized at the indicated times and lysates were precipitated
using serum derived from patient 7. While phosphorylation
of pp46 is rapidly induced in Jurkat (neo) control cells in
response to gamma irradiation (Fig. 6 B, right), pp46 is ab-
sent from Jurkat (bcl-2) transformants treated with this
same stimulus (Fig. 6 B, left). Qualitatively similar results
are seen with UV irradiation (Fig. 6 C), although a small
amount of pp46 is observed in Jurkat (bcl-2) transformants
beginning at 4.5 h. Overexpression of bcl-2 effectively in-
hibited apoptosis in response to these triggers, as judged by
the induction of DNA fragmentation (data not shown). In
contrast, phosphorylation of pp46 after Fas ligation was rel-
atively unaffected by overexpression of bcl-2 (Fig. 6 A).
The induction of DNA fragmentation after Fas ligation was
similarly unaffected by overexpression of bcl-2 in these
cells (data not shown), supporting the correlation between
phosphorylation of pp46 and the induction of apoptosis. A
similar inhibitory effect of bcl-2 after gamma and UV irra-
diation but not anti-Fas treatment, on the phosphorylation
of pp54, pp34, and pp17 (Fig. 1 A and Table 1) recognized
by serum from patient 11, was also observed (data not
shown). Taken together, these results demonstrate that the
in vivo phosphorylation of all four autoantigens that were
Figure 6. In vivo phosphorylation of pp46 correlates with the induc-
tion of apoptosis and is inhibited in Jurkat cells overexpressing bcl-2. Jur-
kat transformants (bcl-2, left) or Jurkat control transformants (neo, right)
were labeled with 32P-orthophosphate, subjected to the indicated apop-
totic stimulus, solubilized in NP40 lysis buffer, and precipitated using se-
rum derived from patient 7 before electrophoretic separation. (A) Anti-
Fas treatment; (B) gamma irradiation; (C) UV irradiation. The relative
migration of molecular size markers in kilodaltons is indicated on the
right side of each panel. The time, in hours, from initial exposure to each
stimulus is indicated at the top of each lane.851 Utz et al.
tested correlated with the induction of apoptosis, and is
downstream of the inhibitory effects of bcl-2.
Discussion
SLE is characterized by the production of autoantibodies
that recognize a restricted subset of intracellular proteins
and nucleic acids (1). Autoantibodies reactive with single-
and double-stranded DNA, as well as nuclear RNP com-
plexes are responsible, in part, for the ability of lupus serum
to bind to the nuclei of cultured cells (1, 5). Antinuclear
antibodies are almost always found in the serum of patients
with SLE, and their presence has both diagnostic and
pathogenic implications in this disease. Specific autoanti-
body profiles are associated with disease subsets (e.g., anti–
Jo-1 histidyl tRNA synthetase and myositis) and are pre-
dictive of future disease manifestations (e.g., anti–Jo-1 and
interstitial lung disease; 36, 37). Other autoantibodies have
been shown to be directly pathogenic in animal models and
in human disease, including anti-DNA antibodies (im-
mune-complex glomerulonephritis), antiphospholipid anti-
bodies (antiphospholipid antibody syndrome, characterized
by arterial and venous thromboses and recurrent fetal loss),
and anti-Ro antibodies (congenital heart block in the neo-
natal lupus syndrome) (36–40).
Evidence continues to mount that defects in apoptosis
are at least partially involved in the pathogenesis of SLE.
The genetic defects responsible for the lupus-like diseases
found in MRL/lpr/lpr and C3H/HeJ-gld/gld mice have
been identified as the genes encoding Fas and Fas ligand,
respectively, a receptor–ligand pair required for activation-
induced death of lymphocytes (41, 42). Additional evi-
dence linking defects in apoptosis to the pathogenesis of
SLE comes from studies showing that proteins cleaved by
ICE family proteases during apoptosis are common targets
for autoantibody production in patients with SLE. This
autoantigenic subset includes several DNA repair enzymes,
including poly (A) ribose polymerase and the catalytic sub-
unit of DNA-PK (7, 43, 44). Several autoantigens are con-
centrated at membrane blebs rimming the surface of kerati-
nocytes undergoing apoptosis. Although the role of these
membrane blebs in antigen presentation is not known, these
results suggest the intriguing possibility that proteins modi-
fied during apoptosis may be preferred targets for autoanti-
body production (6–8, 11, 43, 44). Further support for this
hypothesis comes from two recent studies demonstrating
that immunization of mice with apoptotic cells leads to the
production of autoantibodies, including antibodies directed
against DNA-PK (Zhang, C., and S. Schlossman, unpub-
lished data; and 12, 13). This possibility led us to screen se-
rum from patients with autoimmune disease for antibodies
reactive with proteins that are phosphorylated during apop-
tosis. Our results indicate that substrates of serine/threonine
kinases activated during stress-induced apoptosis are com-
monly included in precipitates from apoptotic cells using
serum from patients with SLE. Using a more stringent
ANA titer of >1:160 as a cutoff value, as opposed to the
>1:20 titer used in initial patient selection, demonstrates
that at least one new phosphoprotein is observed in 9/10
ANA 1 sera, and all nine sera from SLE or SLE overlap
patients. It should be emphasized, however, that the small
number of patients presented in this initial study precludes
generalizations about disease associations or prevalence of
autoantigen phosphorylation. Future studies using sera
from larger numbers of patients with well-defined clinical
syndromes and carefully defined serologic characteristics
will clarify the importance of autoantigen phosphorylation
in autoimmune disease.
Stress-activated serine/threonine kinases (SAP kinases,
also referred to as JNK and p38) play an essential role in
signaling stress-induced apoptosis (15–17, 30, 31, 45). Sev-
eral transcription factors (e.g., c-Jun, Elk-1, and ATF-2) are
substrates for SAP/JNK/p38, and dominant inhibitory mu-
tations in c-Jun can block stress-induced apoptosis, suggest-
ing that stress-activated kinases influence apoptosis at the
transcriptional level. The kinase activity responsible for phos-
phorylation of pp46 has several similarities to the SAP/JNK
kinases, including a requirement for magnesium and man-
ganese but not calcium, resistance to RNase and DNase
treatment (data not shown), and identical kinetics of phos-
phorylation and serine specificity (15–17, 30, 31, 45). An-
other stress-activated serine/threonine kinase that has been
implicated in a signaling cascade leading to apoptosis is FAST
kinase (25, 46). FAST kinase phosphorylates TIA-1, but
not TIAR, two related RNA-binding proteins that appear
to regulate mRNA translation (Kedersha, N., and P. Ander-
son, unpublished observations) and have been shown to
translocate from the nucleus to the cytoplasm during Fas-
mediated apoptosis (25, 47). We have identified autoanti-
bodies reactive with TIA-1 and TIAR in the sera of z2%
of patients with a positive ANA (Utz, P.J., and P. Ander-
son, unpublished observations), consistent with our hypoth-
esis that proteins phosphorylated during apoptosis are pre-
ferred targets for autoantibody production. Additional
kinases that may be involved in signaling apoptosis include
protein kinase C (48), cyclin dependent kinases (49–52),
cAMP kinase I (53, 54), casein kinase I (55), Pim-1 (56),
Wee-1 (57), and PITSLRE kinases (28). Further character-
ization of the kinase activities described in this report is on-
going and should allow identification of the responsible ki-
nase(s) and elucidation of their role in autoantibody
production and programmed cell death.
The identity of the seven kinase substrates described in
this report is not known. Over 100 autoantigens have been
identified to date, some of which are known phosphopro-
teins, including the ribosomal proteins P0, P1, and P2 that
are similar in size to the pp17 doublet and pp42 (1). It is
possible that these substrates are novel, apoptosis-specific
proteins, and perhaps are part of the core apoptotic ma-
chinery. A second possibility is that the observed bands
may represent proteolytic cleavage products of larger phos-
phoproteins, as would be predicted for a phosphoprotein
such as DNA-PK. The disappearance of the weakly (and
variably) phosphorylated 68-kD band precipitated from non-
apoptotic cell lysates with serum from patient 7 (Figs. 1 A,
5, and 6) and the subsequent appearance of pp46 in precip-852 Phosphorylation of Autoantigens during Apoptosis
itates from apoptotic lysates support this possibility, although
the marked increase in phosphorylation of pp46 both in
vivo and in vitro argues strongly for a new phosphorylation
event. Cleavage and phosphorylation are not necessarily
mutually exclusive events, and it remains plausible that serine
phosphorylation during apoptosis may target these autoan-
tigens or other proteins in a macromolecular complex for
cleavage by an ICE-like protease. Comparison of the sizes
of the phosphoproteins, presented in Fig. 1 and Table 1,
with the published sizes of ICE-like protease cleavage prod-
ucts demonstrates similarities with U1-70 kD (40-kD prod-
uct) and pp42 (6); nuclear lamin B (68-kD precursor and
45-kD product) and pp46 (10, 58); UBF/Nor-1 (55-, 35-,
32-, and 24-kD products) and pp54, pp34, and pp23, re-
spectively (9); and an unidentified protein fragment of 35-kD
(patient RW) and pp34 (7). A focus of future studies will be
to identify each of these seven phosphoproteins and to iden-
tify their role in apoptosis and autoantibody production.
In vivo autoantigen phosphorylation was inhibited in
cells overexpressing bcl-2 after UV or gamma irradiation, but
not after Fas stimulation. Programmed cell death, as assayed
by DNA fragmentation and characteristic cell morphologic
changes, correlated precisely with antigen phosphorylation
for each stimulus. This, together with the observation that
none of the autoantigens was phosphorylated in response to
CD3 stimulation, suggests that the phosphorylation of au-
toantigens is specifically correlated with the activation of
intrinsic cell death pathway(s) and is not an epiphenome-
non associated with stress stimuli. Although the molecular
mechanisms by which bcl-2 inhibits apoptosis are not
known, it appears to act at a signaling step preceding the
activation of the protease apopain/CPP32 (32–35). Recent
results showing physical interactions between bcl-2 family
members and serine/threonine kinases involved in signal-
ing cell growth (e.g., raf-1) suggest that activation of kinase
cascades similar to the cascade (s) described in this report
might precede the activation of ICE family proteases under
some conditions (59–61).
The self antigens recognized by autoantibodies found in
lupus serum comprise a small subset of total cellular pro-
teins. It is striking that many of these antigens are substrates
for proteases and kinases involved in signaling or execution
of apoptotic cell death. Why are proteins modified during
apoptosis preferred targets for autoantibody production in
patients with SLE? Perhaps a clue comes from the observa-
tion that some autoantigens are concentrated at membrane
blebs formed at the surface of apoptotic cells (8, 11). Phos-
phorylation during apoptosis of the protein constituents of
macromolecular complexes such as RNPs may produce neo-
epitopes or may target individual proteins for proteolysis
and/or translocation to membrane blebs, as has been ob-
served for the U1-70–kD protein (6, 8). Although intracel-
lular antigens presented on the surface of apoptotic cells
might be recognized by self-reactive B lymphocytes, a pro-
ductive immune response would not be generated in the
absence of antigen-specific helper T cells. It is possible,
however, that proteolysis or phosphorylation of selected
proteins during apoptosis produces neoepitopes to which
T cells are not tolerized. In the special case in which the
apoptotic cell is also an APC, priming of naive T cells may
ensue. T cell recognition of modified self proteins pre-
sented by apoptotic APCs could drive the differentiation
and expansion of autoreactive B cells, resulting in autoanti-
body production. This hypothesis requires that APCs from
patients with SLE are unusually sensitive to stress-induced
apoptosis. This sensitivity could be conferred by a combi-
nation of genetic and environmental factors.
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